Natasja Brooijmans

Large Scale Meta-Analysis of Fragment-Based Screening Campaigns

Anne Mai Wassermann, Meir Glick, S Kirk Wright, 2015, Journal of biomolecular screening.

A Protein Relational Database and Protein Family Knowledge Bases to Facilitate Structure‐Based Design Analyses

Ramaswamy Nilakantan, Christine Humblet, Eric Feyfant, 2010, Chemical biology & drug design.

Kinase domain mutations in cancer: implications for small molecule drug design strategies.

Allan Wissner, Natasja Brooijmans, N. Brooijmans, 2009, Journal of medicinal chemistry.

Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor.

Judy Lucas, Irwin Hollander, Robert Mallon, 2010, Journal of medicinal chemistry.

Stability of macromolecular complexes

Irwin D Kuntz, Natasja Brooijmans, I. Kuntz, 2002, Proteins.

A lead discovery strategy driven by a comprehensive analysis of proteases in the peptide substrate space

Rajiv Chopra, Meir Glick, Florian Nigsch, 2010, Protein science : a publication of the Protein Society.

Structure-Based Drug Design

Kunbin Qu, Natasja Brooijmans, N. Brooijmans, 2007 .

Inside the Mind of a Medicinal Chemist: The Role of Human Bias in Compound Prioritization during Drug Discovery

Meir Glick, John D. Coley, Peter S. Kutchukian, 2012, PloS one.

Discovery of potent and selective inhibitors of the mammalian target of rapamycin (mTOR) kinase.

Joshua Kaplan, Irwin Hollander, Natasja Brooijmans, 2009, Journal of medicinal chemistry.